MedTrace Logo

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-06-14

No results posted yet for this study

Summary

This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.

Conditions

Interventions

DRUG

Bosutinib

100mg daily for 4 cycles (21 days per cycle)

DRUG

Pemetrexed

500 mg/m2 every 21 days for 4 cycles

Sponsors & Collaborators

  • Nagla Abdel Karim

    lead OTHER

Principal Investigators

  • Nagla Karim, MD · Augusta University Georgia Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2022-05-10
Completion
2022-05-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023319 on ClinicalTrials.gov